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What is Noonan’s syndrome 
(NS)?
■ Noonan syndrome is a pleiomorphic 
autosomal dominant disorder with cardinal 
features such as short stature, distinctive 
facial dysmorphia, webbed neck, and heart 
defects
■ Noonan syndrome (NS) is a relatively 
common congenital disease that affects both 
males and female equally
http://rarediseases.org/rare-diseases/noonan-syndrome 
http://www.news-medical.net/health/Noonan-Syndrome-History.aspx
History 1.2.
▪ The first reported patient with what is now called Noonan 
syndrome was reported by Kobylinski in 1883: the individual in 
question was a 20-year old male with marked webbing of the neck, 
which was a feature that seemed to prompt a majority of the early 
reports
▪ In 1902, Funke described a patient with a webbed neck, who also 
presented with a short stature, cubitus valgus (a deformity of the 
elbow), micrognathia (undersized jaw) and other minor 
abnormalities
▪ Reports of so-called “male Turner syndrome” or Turner phenotype 
have been abundant throughout the 1960s, but a vigorous attempt 
to find an underlying chromosomal abnormality was unsuccessful
http://www.news-medical.net/health/Noonan-Syndrome-History.aspx
History 2.2.
▪ In 1962, a pediatric cardiologist Jacqueline Noonan presented a clinical 
study of associated non-cardiac malformations in children with congenital heart 
disease at the Midwest Society for Pediatric Research, where she also described 
nine patients that shared distinctive facial features and who had a short stature, 
pulmonary stenosis and significant chest deformities
▪ In 1968 she published these nine and an additional ten patients in the American 
Journal of Diseases of Children
▪ Pediatrician John Opitz proposed the eponym Noonan syndrome, which was 
adopted in recognition of dr. Noonan, as she was the first to indicate that this 
condition occurs in both sexes, is familial in certain cases, includes congenital 
heart defects and is associated with normal chromosomes
▪ In 1994, the gene for Noonan syndrome was mapped to the long arm of 
chromosome 12 and named NS1
▪ Noonan syndrome is now known to be a genetically heterogeneous disorder with 
practically one half of all cases caused by gain-of-function mutations in PTPN11, 
the gene encoding the SHP-2
http://www.news-medical.net/health/Noonan-Syndrome-History.aspx
Synonyms of NS
■ Female pseudo-Turner syndrome
■ Male Turner syndrome
■ NS
■ Turner phenotype with normal chromosomes 
(karyotype)
http://rarediseases.org/rare-diseases/noonan-syndrome/
Incidence
■ It is believed that between approximately 1 in 1000 
and 1 in 2500 children worldwide are born with NS
■ It is one of the most genetic syndromes associated 
with congenital heart disease, similar in frequency to 
DOWN SYNDROME
■ However, the range and severity of features can vary 
greatly in patients with NS
■ Therefore, the syndrome is not always identified at 
an early age
https://prezi.com/0re-mynnk5g4/noonan-syndrom/
https://www.google.co.il/search?q=autosomal+dominant+inheritance&biw=1366&bih=667&tbm=isch&tbo=u&source=univ&sa=X&ved=0ahUKEwjRqPmrjMHL
AhUBJJoKHVZED88QsAQIHg#imgrc=DzwwJSTK4yH58M%3A
Causes of NS
■ NS is caused by a genetic mutation and is 
acquired when a child inherits a copy of an 
affected gene from a parent
■ Types - based on the gene in which mutation has 
occurred, NS is of 5 types:
1. NS1 – PTPN11 (50%)
2. NS2 – Unknown (autosomal recessive)
3. NS3 – KRAS (less than 5%)
4. NS4 – SOS1 (13%)
5. NS5 – RAF1 (3-17%)
http://rarediseases.org/rare-diseases/noonan-syndrome/
Characteristics of NS
■ The 3 most common features :
1. Unusual facial features
2. Short stature (restricted growth)
3. Heart defects present at birth (congenital heart disease)
Unusual features :
1. A broad forehead
2. Drooping eyelids (ptosis)
3. A wider-than-usual distance between the eyes
4. A short, broad nose
5. Low-set ears that are rotated towards the back of the head
6. A small jaw
7. A short neck with excess skin folds
8. A lower-than-usual hairline at the back of the head and neck
http://www.nhs.uk/Conditions/noonan-syndrome/Pages/symptoms.aspx

Clinical features
http://www.aafp.org/afp/2014/0101/p37.html
Differential diagnoses
■ Costello syndrome
■ Craniofaciocutaneous syndrome
■ Fetal hydantoin syndrome
■ Lentigines, electrocardiographic (conduction 
abnormalities), ocular (hypertelorism), pulmonary 
(stenosis), abnormal (genitalia), retardation (of 
growth), and deafness (LEOPARD) syndrome
■ XO/XY mosaicism
■ Turner syndrome
■ Neurofibromatosis type 1
■ SPRED1 spectrum
http://emedicine.medscape.com/article/947504-differential
Complications of the NS
■ Developmental issues
■ Bleeding and bruising
■ Complications from lymphatic 
conditions 
■ Genital and urinary tract 
complications
http://www.mayoclinic.org/diseases-conditions/noonan-syndrome/basics/complications/con-20028908
Our patient profile
■ 23 years old (05.10.1993)
■ Male
■ Works as an engineer
■ Lives in a town
■ Hospitalized for a planned course of treatment on 
29.02.16 
Complaints
■ Dyspnea (observed during physical 
exertion(climb to the 7th floor) and relieved 
at rest)
■ Dizziness (sometimes!) – when he changes 
his body position from horizontal to vertical 
(orthostasis)
■ General fatigue
Medical history
■ Congenital heart disease was diagnosed in the hospital 
at birth
■ In 2002 an endovascular dilation of valvular stenosis of 
the pulmonary artery was made
■ He is being under a heart surgeon supervision at the 
Institute of MHS Amosov with diagnosis : Condition 
after endovascular dilation of valvular stenosis of the 
pulmonary artery
■ Residual pulmonary stenosis, secondary atrial septal 
defect
■ Last consultation on 03.07.13 he was recommended to 
undergo a conductive plastic surgery by an occluder for 
the atrial septal defect  
History of life
■ Was born in a full family
■ In 2001 he underwent tonsillectomy
■ Denies tuberculosis, malaria, viral hepatitis, sexually 
transmitted diseases and AIDS
■ Denies allergic reactions to drugs
■ Denies smoking
■ Denies alcohol consumption
■ Hereditary ( Father – essential hypertension, IHD, 
MI)
Objective state 1.6.
■ The general condition is satisfactory, consciousness is 
clear, emotionally stable, optimistic mood
■ Height = 168 cm, Weight = 70 kg
■ Skin is normal
■ Peripheral lymph nodes are not palpable
■ The thyroid is not palpable
Objective state 2.6.
■ Respiratory system :
-Pulmonary percussion-resonant sound
-Pulmonary auscultation-vesicular breathing (no adventitious 
sounds)
■ Cardiovascular system :
-Apex in 5th intercostal space (normal) evidence of RV and RA 
enlargement
-HR=48 bpm
-Auscultation of the heart-continues diffuse parasternal systolic 
murmur, pulmonary valve diastolic murmur, tricuspid valve 
systolic murmur, mitral valve mild systolic murmur, aortic valve-
normal sounds (no evidence of murmur)
-BP sin=112/74 mmHg, BP dextr=110/72 mmHg
Objective state 3.6.
■ Gastrointestinal system :
-Abdomen is soft, painless, symmetrical
-No visible peristalsis
-Liver is not palpated
-Spleen and pancreas are not palpated
■ Triangular face shaped
■ Webbed neck
■ Small chin
■ Thick helix
■ Incomplete folding ears
■ Low set and widely 
spaced nipples
■ Mild signs of 
gynecomastia
Objective state 4.6.
■ Webbed neck
■ Low posterior hairline
Objective state 5.6.
■ Ocular hypertelorism
■ Drooping of the upper eyelids (ptosis)
■ “Hooded” eyelids
Objective state 6.6.
Examination
■ Examinations in the hospital: 
1. Complete blood test
2. General urine test
3. ECG
4. EchoCG 
5. Biochemical blood tests
■ Additional instrumental 
methods : 
1. Ultrasonography of the 
abdomen (liver, gallbladder, 
pancreas, kidney)
2. Holter monitoring
■ Our additional recommended 
examinations:
1.Genetic counselling
2. Fertility issues
3.Neuropsychological and 
behavioral issues
4.Coagulation screening
5.Thyroid screening
6.Dental screening
7.Vision screening
Noonan, J. A. (1994). "Noonan Syndrome: An Update and Review for the Primary Pediatrician." Clinical Pediatrics 33(9): 548-555.  Allanson, J. E. 
(1987). "Noonan syndrome." Journal of Medical Genetics 24(1): 9-13.
Complete blood test 
(01.03.16) 1.2.
MEASURE RESULT RATE
RBC 5,37 4,00 – 5,00 (10^12/L)
Hemoglobin 167 130 – 160 (g/l)
HCT 48,2 40,0 – 48,0 %
MCV 89,8 80,0 – 100,0 (fL)
MCH 31,1 28,0 – 36,0 (pg)
MCHC 346 310 – 370 (g/l)
RDW-CV 13,6 10,0 – 16,5 (%CV)
PLT 303 180 – 320 [10^9/L]
PCT 0.17 0.10 –1.00 (%)
MPV 5.7 5.0 – 10.0 [fL]
PDW 17.3 12.0 – 18.0 [%]
ESR 2 M 2-12 mm/h
Complete blood test (01.03.16) 
2.2.
MEASURE RESULT RATE
WBC 7,0 4,0 - 9,0 (10^9/L)
Neutrophils 63,8 47-72 %
Lymphocytes 27,7 19-37%
Monocytes 4,6 3-11 %
Eosinophils 2,9 0,5-5,0% 
Basophils 1 1-1,0 %
Conclusion : slight elevation in RBCs , HGB ,HCT values may be due to 
compensatory mechanism in response to decrease in O2 saturation due to PH  
General urine test (01.03.16)
MEASURE RESULT NORMAL RANGE 
SPECIFIC GRAVITY 1,026 1,001-1,040
REACTION 5,5 5,0-7,0
PROTEIN absent to 0.033 g / l 
GLUCOSE absent Absent 
LEUCOCYTES 2-3 6-8 
EPITHELIUM 
TRANSITION
Not detected Not detected 
BACTERIA Not detected Not detected 
Conclusion: normal 
Biochemical blood test 
(01.03.16)
MEASURE RESULT NORMAL RANGE 
AsAt 16 <37 u/L
AlAt 18 <41 u/L
Total bilirubin 10.18 8,6-25,5 mcmol/L 
Fasting glucose 5.57 4,2-6,1 mmol/l
Creatinine 72 80-115 mcmol/L
Conclusion: normal
ECG (01.03.16) 1.4.
Conclusion of the ECG 2.4.
■ Sinus rhythm, irregular
■ Sinus arrest during inhale (pause 3035 ms) -
asymptomatic
■ RBBB morphology
■ Right ventricular hypertrophy with strain
■ Heart rate (HR)-47 beats  per min (bpm)
ECG (01.03.16) 3.4.
Conclusion of the ECG 4.4.
■ Sinus (respiratory) arrhythmia
■ RBBB morphology
■ Right ventricular hypertrophy with strain
■ HR- 58 bpm
Echocardiography (01.03.16) 
1.4.
NAME RESULT NORMAL
Acoustic window middling good
Aorta 29,6 20-37 mm
Aortic valve 19,3 17-26 mm
Left atrium 33,6 <38 mm
EDV of LV 46,2 35-55 mm
ESV of LV 31,5 23-38 mm
Mitral valve Physiological regurgitation 1 degree
Posterior wall of LV 10,6 6-11 mm
Interventricular 
septum
11,6 6-11 mm
Right ventricle 31,6 9-26 mm
Echocardiography 2.4.
NAME RESULT NORMAL
Right atrium 45,2 <44 mm
Tricuspid valve Physiological regurgitation 
I-II degree
Pulmonary valve Cusps abnormal changed
Regurgitation I-II degree
The amplitude of the wave 
“a” -2 mm
Vmax=282.4 sm/sec
P gradient=31,6 mm Hg
MPAP=21,7 mm Hg
The amplitude of the wave 
“a” = 4-10 mm
Ejection fraction 60 55-78%
Echocardiography 3.4.
NAME RESULT NORMAL
Interatrial septum Violation of the integrity of 
the atrial septum in the 
middle part of the 
projection - defect IAS up 
to 8.3 mm and abnormal 
reflux from the left atrial 
cavity to the right with 
Gpeak about 4,8 mm Hg
Conclusion of EchoCG 4.4.
■ Signs of pulmonary valve stenosis 1nd degree
■ RV hypertrophy
■ Dilation of the RV and RA
■ Mitral regurgitation 1st degree
■ Tricuspid and pulmonary valve regurgitation 1st and 
2nd degree
■ Pulmonary hypertension 1st stage
■ Defect of the central part of atrial septum with left to 
right shunt  
■ Additional chord in the left ventricular lumen, not 
hemodynamically significant
Holter monitoring (03.03.16) 1.2.
Conclusion : 
■ Against the background of sinus rhythm with RBBB 
average daily HR - 74 beats / min and mean nocturnal 
HR - 54 bpm, recorded maximum HR- 181 bpm 
(patient " ran up the stairs " ) and minimal HR - 38 
bpm at 05:22:05
■ Circadian index 1,37 (N 1,24-1,44)
■ During the entire period of monitoring were recorded 
frequent sinoatrial blockades II degree Mobitz 1 and 
Mobitz  2 with a maximum pause -1832 ms at 23:19
■ Also a single ventricular premature beats were 
recorded (total 2 )
Holter monitoring (03.03.16) 2.2.
(an example of SA block II degree  from the recording)
Ultrasonography of the 
abdomen (01.03.16)
■ Conclusion : 
1. kidney salt diathesis
2. Right nephroptosis 
Consultation of heart surgeon-
arrhythmologist (10.09.16)
Conclusion:
❑According to Holter ECG with
solitary episodes of SA blockades and
solitary asymptomatic episode of
sinus arrest (01.03.16) are not
clinically significant
❑There are no indications for
pacemaker implantation
Basic clinical syndromes
❑ Congenital heart defects
❑ Pulmonary hypertension
❑ Erythrocytosis, hemoconcentration
❑ Arrhythmias (persistent SA blockade)
❑ Heart failure
❑ Multiple  stigmas of disembryogenesis
THE CLINICAL DIAGNOSIS 
ACCORDING TO CURRENT 
CLASSIFICATIONS
Diagnostic features of NS (Van 
Der Burgt 1997
Feature A=MAJOR B=MINOR
1.Facial Typical face (facial features 
of NS vary over time)
Suggestive face
2.Cardiac Pulmonary valve stenosis 
and/or hypertrophic 
cardiomyopathy
Other cardiac defect
3.Height < 3rd centile < 10th centile
4.Chest wall Pectus carinatum/excavatumBroad thorax
5.Family history 1st degree relative with 
definite NS
1st degree relative 
suggestive of NS
6.Other Mild developmental delay, 
cryptorchidism and 
lymphatic dysplasia
Mild developmental delay, 
cryptorchidism and 
lymphatic dysplasia
http://ojrd.biomedcentral.com/articles/10.1186/1750-1172-2-4
Definitive NS
Criterion 1A+ Criterion 1B+
▪ One of 2A-6A
▪ Two of 2B-6B
▪ Two of 2A-6A
▪ Three of 2B-6B
http://ojrd.biomedcentral.com/articles/10.1186/1750-1172-2-4
Sinoatrial (SA) block
Classification
★ In 1st-degree SA block, the SA node impulse is merely slowed, and 
ECG is normal
★ Second degree sinoatrial block is categorized into type I and type II
★ 2nd-degree type I SA block (Wenckebach) demonstrates progressive 
shortening of the R-R or P-P intervals until a P wave is blocked in the 
SA node (which would not appear on the ECG)
★ 2nd-degree type II SA block occurs when there are consistent R-R and 
P-P intervals, then a P wave is blocked in the SA node (not seen on the 
ECG);the subsequent "sinus pause" is an exact interval of the 
preceding R-R intervals (usually two times)
★ In 3rd-degree SA block, conduction is blocked; P waves are absent, 
giving the appearance of sinus arrest
Functional classification of pulmonary 
hypertension modified after the NYHA functional 
classification according to the WHO 1998
https://www.escardio.org/static_file/Escardio/Guidelines/Publications/PAH/2015%20ESC-ERS%20Gles%20PH-Web%20addenda-ehv317.pdf
Class Objective Assessment
I Patients with pulmonary hypertension but without resulting limitation of 
physical activity. Ordinary physical activity does not cause undue dyspnoea 
or fatigue, chest pain or near syncope
II Patients with pulmonary hypertension resulting in slight limitation of physical 
activity. They are comfortable at rest. Ordinary physical activity causes 
undue dyspnoea or fatigue, chest pain or near syncope
III Patients with pulmonary hypertension resulting in marked limitation of 
physical activity. They are comfortable at rest. Less than ordinary activity 
causes undue dyspnoea or fatigue, chest pain or near syncope
IV Patients with pulmonary hypertension with inability to carry out any physical 
activity without symptoms. These patients manifest signs of right heart 
failure. Dyspnoea and/or fatigue may even be present at rest. Discomfort is 
increased by any physical activity
Clinical classification of pulmonary arterial
hypertension associated with congenital heart 
disease 
http://eurheartj.oxfordjournals.org/content/early/2015/08/28/eurheartj.ehv317
1. Eisenmenger’s syndrome
Includes all large intra- and extra-cardiac defects which begin as systemic-to-pulmonary shunts and progress with
time to severe elevation of PVR and to reversal (pulmonary-to-systemic) or
bidirectional shunting; cyanosis, secondary erythrocytosis, and multiple organ involvement are usually present
2. PAH associated with prevalent systemic-to-pulmonary shunts
• Correctablea
• Non-correctable
Includes moderate to large defects; PVR is mildly to moderately increased, systemic-to-pulmonary shunting is still 
prevalent, whereas cyanosis at rest is not a feature.
3. PAH with small/coincidental defects (b
Marked elevation in PVR in the presence of small cardiac defects (usually ventricular septal defects <1 cm and 
atrial septal defects <2 cm of effective diameter assessed by echo), which themselves do not account for the 
development of elevated PVR; the clinical picture is very similar to idiopathic PAH. Closing the defects is contra-
indicated.
4. PAH after defect correction
Congenital heart disease is repaired, but PAH either persists immediately after correction or recurs/develops 
months or years after correction in the absens of significant postoperative haemodynamic lesions.
PAH = pulmonary arterial hypertension; PVR = pulmonary vascular resistance.
a With surgery or intravascular percutaneous procedure.
b The size applies to adult patients. However, also in adults the simple diameter may be not sufficient for defining the haemodynamic 
relevance of the defect and also the pressure gradient, the shunt size and direction, and the pulmonary to systemic flows ratio should 
be considered
Echocardiographic and Doppler parameters used 
in grading pulmonary regurgitation severity
http://www.ncbi.nlm.nih.gov/pubmed/12835667?dopt=Abstract
Parameter Mild Moderate Severe
Pulmonic valve Normal Normal or abnormal Abnormal
RV size Normal Normal or dilated Dilated
Jet size by color 
Doppler§
Thin (usually < 10 
mm in length) with 
a narrow origin
Intermediate
Usually large, with a 
wide origin; May be 
brief in duration
Jet density and 
deceleration rate –
CW†
Soft; Slow 
deceleration
Dense; variable 
deceleration
Dense; steep 
deceleration, early 
termination of 
diastolic flow
Pulmonic systolic 
flow compared to 
systemic flow –PWφ
Slightly increased Intermediate Greatly increased
THE NEW YORK HEART ASSOCIATION 
(NYHA) FUNCTIONAL CLASSIFICATION 
(FUNCTIONAL CAPACITY) OF CHF
http://www.heart.org/HEARTORG/Conditions/HeartFailure/AboutHeartFailure/Classes-of-Heart-Failure_UCM_306328_Article.jsp#.VnJyxEqLQdU
Class Patient Symptoms
I
No limitation of physical activity. Ordinary physical activity 
does not cause undue fatigue, palpitation, dyspnea 
(shortness of breath).
II
Slight limitation of physical activity. Comfortable at rest. 
Ordinary physical activity results in fatigue, palpitation, 
dyspnea (shortness of breath).
III
Marked limitation of physical activity. Comfortable at rest. 
Less than ordinary activity causes fatigue, palpitation, or 
dyspnea.
IV
Unable to carry on any physical activity without discomfort. 
Symptoms of heart failure at rest. If any physical activity is 
undertaken, discomfort increases.
AMERICAN HEART ASSOCIATION 
HEART FAILURE STAGES
http://www.sunshineheart.com/patients/classification-of-heart-failure/
Class Objective Assessment
A No objective evidence of cardiovascular disease. No symptoms and 
no limitation in ordinary physical activity.
B Objective evidence of minimal cardiovascular disease. Mild 
symptoms and slight limitation during ordinary activity. Comfortable 
at rest.
C Objective evidence of moderately severe cardiovascular disease. 
Marked limitation in activity due to symptoms, even during less-
than-ordinary activity. Comfortable only at rest.
D Objective evidence of severe cardiovascular disease. Severe 
limitations. Experiences symptoms even while at rest.
Classification of the severity of 
pulmonary stenosis
Mild Moderate Severe
Peak velocity 
(ms)
<3 3-4 >4
Peak gradient 
(mm Hg)
<36 36-64 >64
http//www.echopedia.org/index.php/normal_values
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Complete diagnosis
■ Health facility 
diagnosis : 
- CHD : condition after endovascular 
dilatation pulmonary valve stenosis 
(2002)
- Residual pulmonary valve stenosis
- Pulmonary valve insufficiency
- Secondary atrial septal defect
- Transient sinoatrial block II  
degree
- HF II A stage, II FC 
■ Our clinical diagnosis :
Main:
- Noonan’s syndrome
( - CHD : condition after endovascular 
dilatation pulmonary valve stenosis (2002)
- Residual pulmonary valve stenosis I degree 
(mild severity)
- Pulmonary valve insufficiency II degree 
(moderate severity)
-Secondary atrial septal defect with left to 
right shunt
-Transient sinoatrial block II degree type I)
Complication: 
- Pulmonary hypertension I class
- Right heart failure I FC,  stage  B
Treatment at the hospital
■ Meldonium - 5,0 IV
■ Trimetazidine- 35 mg twice a 
day 
Treatment 1.3.
Lifestyle modification
Diet
■ Eat vegetables and fruits and limit juice intake
■ Use vegetable oils and soft margarines low in saturated fat and 
trans fatty acid instead of butter or most animal fats
■ Eat whole-grain rather than refined-grain bread and cereals
■ Reduce intake of sugar-sweetened beverages and foods
■ Use nonfat or low-fat (one percent) milk
■ Increase fish consumption, use only lean cuts of meat and reduced-
fat meat products, and remove the skin from poultry
■ Reduce salt intake
■ Teach about a balanced meal, portion size and caloric contents of 
snacks
■ Limit eating out and encourage eating at home
http://www.secondscount.org/healthy-living/healthy-living-detail-2/living-with-congenital-heart-disease-choosing-good#.Vvosb-KLQd
Treatment 2.3.
Lifestyle modification
■ Patient require sensible advice about general activities of daily living 
and need to adapt to the uncertainty associated with a serious 
chronic life-threatening disease
■ Immunization of PAH patients against influenza and pneumococcal 
infection is recommended
■ Psychosocial support is recommended in PAH patients
■ Supervised exercise training should be considered in physically 
deconditioned PAH patients under medical therapy
■ In elective surgery, epidural rather than general anaesthesia should 
be preferred whenever possible
■ Excessive physical activity that leads to distressing symptoms is not 
recommended in PAH patients
http://eurheartj.oxfordjournals.org/content/early/2015/08/28/eurheartj.ehv317
Treatment 2.3.
■ The treatment of Noonan syndrome is directed
toward the specific symptoms that are apparent in
each individual
■ Treatment may require the coordinated efforts of a
team of specialists (pediatricians, cardiologists,
hematologists, endocrinologists and/or other health
care professionals may need to systematically and
comprehensively plan an affected child's treatment)
http://rarediseases.org/rare-diseases/noonan-syndrome
http://www.escardio.org/Guidelines-&-Education/Clinical-Practice-Guidelines/Pulmonary-Hypertension-Guidelines-on-Diagnosis-and-Treatment-of
Recommendations for 
supportive therapy of PAH 1.2.
http://eurheartj.oxfordjournals.org/content/early/2015/08/28/eurheartj.ehv317
Recommendations for 
supportive therapy of PAH 2.2.
http://eurheartj.oxfordjournals.org/content/early/2015/08/28/eurheartj.ehv317
Recommended treatment
■ Sildenafil 25 mg in the morning for 
treatment pulmonary hypertension and 
preventing progression of it
■ Perindopril 1-2 mg in the evening to prevent 
myocardial remodeling
■ Regular cardiac screening
■Planned conductive plastic surgery by an 
occluder for the atrial septal defect  to 
prevent RV failure and as a result fluid 
retention
Recommendations for further 
examination
❖ Genetic counselling
❖ Fertility issues
❖ Neuropsychological and behavioral issues
❖ Coagulation screening
❖ Thyroid screening
❖ Dental screening
❖ Vision screening
Recommendations for pulmonary hypertension 
screening
https://www.escardio.org/static_file/Escardio/Guidelines/Publications/PAH/2015%20ESC-ERS%20Gles%20PH-Web%20addenda-ehv317.pdf
PROGNOSIS
■ Prognosis for life - non-compliance 
with doctor's appointments – non-
satisfactory 
■ The prognosis for recovery - an 
unfavorable
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